# Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day)

> **NCT00514488** · PHASE3 · COMPLETED · sponsor: **University of Bologna**

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** STI571 (400 mg/day; or 800 mg/day)

## Key facts

- **NCT ID:** NCT00514488
- **Lead sponsor:** University of Bologna
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2007-08-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00514488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00514488, "Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00514488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*